EMD-41249

Single-particle
3.3 Å
EMD-41249
3D View Gallery
Deposition: 13/07/2023
Map released: 22/05/2024
Last modified: 29/05/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-41249
Download
3D volume (map.gz) Experimental metadata (xml) Experimental Metadata (cif.gz)
Map-only Validation report (pdf.gz) Map-only Validation report (cif.gz) Map-only Validation report (xml.gz)
Map and PDB model 8th4 summary report (pdf.gz) Map and 8th4 FULL report (pdf.gz)
EMICSS annotations (xml)

Structure of AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor and Losartan

EMD-41249

Single-particle
3.3 Å
EMD-41249
3D View Gallery
Deposition: 13/07/2023
Map released: 22/05/2024
Last modified: 29/05/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: synthetic construct, Homo sapiens
Sample: AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor BRIL Fusion protein, Anti-BRIL Fab, Anti-Fab Nanobody, and Losartan
Fitted models: 8th4

Deposition Authors: Skiba MA, Kruse AC
Antibodies expand the scope of angiotensin receptor pharmacology.
Skiba MA, Sterling SM, Rawson S , Zhang S , Xu H, Jiang H , Nemeth GR, Gilman MSA, Hurley JD , Shen P , Staus DP, Kim J, McMahon C , Lehtinen MK, Rockman HA , Barth P , Wingler LM , Kruse AC
(2024) Nat Chem Biol
PUBMED: 38744986
DOI: doi:10.1038/s41589-024-01620-6
ISSN: 1552-4469